|
Market Closed -
Canadian Securities Exchange
14:49:02 2026-10-29 EDT
|
5-day change | 1st Jan Change | ||
| 0.3500 CAD | 0.00% |
|
-12.50% | -51.39% |
Company Valuation: Defence Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 245.3 | 73.23 | 127.5 | 33.7 | 38.31 | 33.35 |
| Change | - | -70.15% | 74.18% | -73.58% | 13.68% | -12.95% |
| Enterprise Value (EV) 1 | 239.9 | 72.72 | 126.5 | 35.39 | 38.58 | 33.19 |
| Change | - | -69.69% | 73.95% | -72.03% | 9.02% | -13.98% |
| P/E | -65.6x | -9.83x | -17.1x | -2.5x | -9.9x | -4x |
| PBR | 45.3x | -189x | 81.6x | -9.4x | -30.5x | 9.49x |
| PEG | - | -0.1x | 1.1x | -0x | 0.1x | -0.1x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -84.9x | -10x | -19.5x | -2.78x | -12.1x | -6.73x |
| EV / FCF | -201x | -22.4x | -23.7x | 401x | -16.7x | -6.32x |
| FCF Yield | -0.5% | -4.46% | -4.22% | 0.25% | -6% | -15.8% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.1075 | -0.2036 | -0.1705 | -0.2956 | -0.0707 | -0.11 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | -6.481 | -12.68 | -3.144 | -4.858 |
| EBIT 1 | -2.826 | -7.274 | -6.494 | -12.75 | -3.19 | -4.93 |
| Net income 1 | -2.859 | -7.344 | -6.763 | -13.19 | -3.522 | -6.695 |
| Net Debt 1 | -5.453 | -0.5067 | -1.047 | 1.69 | 0.2718 | -0.1613 |
| Reference price 2 | 7.0500 | 2.0000 | 2.9200 | 0.7400 | 0.7000 | 0.4400 |
| Nbr of stocks (in thousands) | 34,801 | 36,615 | 43,681 | 45,537 | 54,725 | 75,788 |
| Announcement Date | 10/27/21 | 10/24/22 | 10/27/23 | 9/20/24 | 10/28/25 | 10/29/26 |
1CAD in Million2CAD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 18.9M | |
| 16.92x | 6.39x | 12.26x | 1.77% | 64.14B | |
| 30.57x | 8.11x | 26.59x | 0.05% | 55.53B | |
| 36.68x | 6.52x | 19.45x | 0.88% | 53.03B | |
| 35.39x | 3.41x | 14.74x | -.--% | 45.99B | |
| 49.25x | 5.68x | 31.09x | -.--% | 42.45B | |
| -19.59x | 189.6x | -20.86x | -.--% | 40.45B | |
| 47.12x | 8.37x | 28.08x | -.--% | 34.47B | |
| 31.7x | 8.06x | 20.96x | 0.41% | 32.25B | |
| 27.96x | 5.9x | 15.29x | -.--% | 24.23B | |
| Average | 28.44x | 26.89x | 16.40x | 0.34% | 39.26B | |
| Weighted average by Cap. | 27.96x | 25.38x | 16.46x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- DTC Stock
- Valuation Defence Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
